EUVIMEDEUVIMED entdecken
Crossref

Prevalence and implications of mogamulizumab-induced immune-related adverse events in mycosis fungoides/Sézary syndrome; a single-center experience

Abdulhadi Jfri, Cesar A Virgen, Marianne Tawa, Anita Giobbie-Hurder, Thomas S Kupper, David C Fisher, Nicole R LeBoeuf, Cecilia Larocca

Journal of the American Academy of Dermatology · 2023-11 · 89 (5) · 1044-1047

DOI: 10.1016/j.jaad.2023.05.082 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of the American Academy of Dermatology, 2023-11. Verfasst von Abdulhadi Jfri und 7 weiteren Autor:innen. Beteiligte Einrichtung: Harvard Medical School, Boston, Massachusetts; Department of Dermatology, Brigham and Women's Hospital, Boston, Massachusetts. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 5 Literaturangaben. Gefördert von: NIAMS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

Stichwörter der Autor:innen

CTCLMARMogamulizumabSézary syndromecutaneous T cell lymphomaimmune-related adverse eventsmycosis fungoidesside effectsskin toxicity

Autor:innen und Institutionen

  • Harvard Medical School, Boston, Massachusetts; Department of Dermatology, Brigham and Women's Hospital, Boston, Massachusetts.
  • Harvard Medical School, Boston, Massachusetts; Department of Dermatology, Brigham and Women's Hospital, Boston, Massachusetts; Center for Cutaneous Oncology, Dana-Farber/Brigham and Women's Cancer Center, Boston, Massac…
  • Center for Cutaneous Oncology, Dana-Farber/Brigham and Women's Cancer Center, Boston, Massachusetts.
  • Division of Biostatistics, Department of Data Science, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Department of Medical Oncology, Dana-Farber/Brigham and Women's Cancer Center, Boston, Massachusetts.

Förderung

  • NIAMS NIH HHS

Zitieren

APA

Jfri, A., Virgen, C. A., Tawa, M., Giobbie-Hurder, A., Kupper, T. S., Fisher, D. C., LeBoeuf, N. R., & Larocca, C. (2023). Prevalence and implications of mogamulizumab-induced immune-related adverse events in mycosis fungoides/Sézary syndrome; a single-center experience. Journal of the American Academy of Dermatology, 89(5), 1044-1047. https://doi.org/10.1016/j.jaad.2023.05.082

Vancouver

Jfri A, Virgen CA, Tawa M, Giobbie-Hurder A, Kupper TS, Fisher DC, et al. Prevalence and implications of mogamulizumab-induced immune-related adverse events in mycosis fungoides/Sézary syndrome; a single-center experience. Journal of the American Academy of Dermatology. 2023;89(5):1044-1047. doi:10.1016/j.jaad.2023.05.082

BibTeX
@article{Jfri2023,
  author = {Jfri, Abdulhadi and Virgen, Cesar A and Tawa, Marianne and Giobbie-Hurder, Anita and Kupper, Thomas S and Fisher, David C and LeBoeuf, Nicole R and Larocca, Cecilia},
  title = {Prevalence and implications of mogamulizumab-induced immune-related adverse events in mycosis fungoides/Sézary syndrome; a single-center experience},
  journal = {Journal of the American Academy of Dermatology},
  year = {2023},
  volume = {89},
  number = {5},
  pages = {1044--1047},
  doi = {10.1016/j.jaad.2023.05.082}
}
Kostenlos starten →